- November 3, 2021
12:00 PM - 5:00 PM ET
- Organized By:
Sponsored by the U.S. Food & Drug Administration (FDA)
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) welcomes you to the Clinical Trial Endpoint Development for Locally Advanced Head and Neck Cancer public virtual workshop. Throughout the day you will hear interactive discussions on early endpoints in locally advanced head and neck squamous cell carcinoma, event-free survival (EFS) and locoregional control (LRC), issues regarding management and defining early endpoints, and patient’s perspective on clinical trial endpoints.
- Provide a forum for open discussion between academia, regulatory, and patient advocacy groups on clinical trial endpoint development for locally advanced head and neck cancer.
- Identify the current status of early endpoints for locally advanced head and neck cancer and how it differs from other cancers.
- Engage stakeholders to identify concerns regarding standardization of endpoint definitions and clinical trial design.
A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above.
FDA plans to post archived webcasts after the meeting, however, in cases where the transmission was not successful, archived webcasts will not be available.
For any inquiries regarding this program, please send an email to: OCE-Engagement@fda.hhs.gov